{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:24:48Z","timestamp":1793744688524,"version":"4.6.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["CSA\/0053\/2013"],"award-info":[{"award-number":["CSA\/0053\/2013"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["CSA\/0053\/2008"],"award-info":[{"award-number":["CSA\/0053\/2008"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["RTF\/MOH\/000616"],"award-info":[{"award-number":["RTF\/MOH\/000616"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["RTF\/MOH\/000302"],"award-info":[{"award-number":["RTF\/MOH\/000302"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["Singapore Translational Research (STaR) Award MOH-000708"],"award-info":[{"award-number":["Singapore Translational Research (STaR) Award MOH-000708"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41591-024-03228-8","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T06:02:01Z","timestamp":1725343321000},"page":"3687-3696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Fratricide-resistant CD7-CAR T cells in T-ALL"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6184-8935","authenticated-orcid":false,"given":"Bernice L. Z.","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6506-2291","authenticated-orcid":false,"given":"Noriko","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Coustan-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn H. R.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Yeap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lip Kun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Y. A.","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0502-2527","authenticated-orcid":false,"given":"Nina","family":"Le Bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-0485","authenticated-orcid":false,"given":"Antonio","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9643-3465","authenticated-orcid":false,"given":"Francesca","family":"Del Bufalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Becilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6454-976X","authenticated-orcid":false,"given":"Allen E. J.","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"3228_CR1","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.4049\/jimmunol.138.4.1260","volume":"138","author":"JJ van Dongen","year":"1987","unstructured":"van Dongen, J. J. et al. T cell receptor\u2013CD3 complex during early T cell differentiation. Analysis of immature T cell acute lymphoblastic leukemias (T-ALL) at DNA, RNA, and cell membrane level. J. Immunol. 138, 1260\u20131269 (1987).","journal-title":"J. Immunol."},{"key":"3228_CR2","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4049\/jimmunol.138.2.648","volume":"138","author":"D Campana","year":"1987","unstructured":"Campana, D., Thompson, J. S., Amlot, P., Brown, S. & Janossy, G. The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage. J. Immunol. 138, 648\u2013655 (1987).","journal-title":"J. Immunol."},{"key":"3228_CR3","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","volume":"20","author":"DT Teachey","year":"2019","unstructured":"Teachey, D. T. & Pui, C.-H. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 20, e142\u2013e154 (2019).","journal-title":"Lancet Oncol."},{"key":"3228_CR4","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.23.00088","volume":"41","author":"EA Raetz","year":"2023","unstructured":"Raetz, E. A. et al. Outcome for children and young adults with T-cell ALL and induction failure in contemporary trials. J. Clin. Oncol. 41, 5025\u20135034 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3228_CR5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","volume":"93","author":"Y Abaza","year":"2018","unstructured":"Abaza, Y. et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am. J. Hematol. 93, 91\u201399 (2018).","journal-title":"Am. J. Hematol."},{"key":"3228_CR6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(05)66998-X","volume":"366","author":"A Balduzzi","year":"2005","unstructured":"Balduzzi, A. et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 366, 635\u2013642 (2005).","journal-title":"Lancet"},{"key":"3228_CR7","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1200\/JCO.2006.06.2679","volume":"24","author":"A Schrauder","year":"2006","unstructured":"Schrauder, A. et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J. Clin. Oncol. 24, 5742\u20135749 (2006).","journal-title":"J. Clin. Oncol."},{"key":"3228_CR8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2011-01-333070","volume":"118","author":"W Leung","year":"2011","unstructured":"Leung, W. et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 118, 223\u2013230 (2011).","journal-title":"Blood"},{"key":"3228_CR9","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","volume":"3","author":"P Bader","year":"2019","unstructured":"Bader, P. et al. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 3, 3393\u20133405 (2019).","journal-title":"Blood Adv."},{"key":"3228_CR10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2021.03.034","volume":"151","author":"C Eckert","year":"2021","unstructured":"Eckert, C. et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur. J. Cancer 151, 175\u2013189 (2021).","journal-title":"Eur. J. Cancer"},{"key":"3228_CR11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","volume":"18","author":"C Imai","year":"2004","unstructured":"Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676\u2013684 (2004).","journal-title":"Leukemia"},{"key":"3228_CR12","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","volume":"13","author":"RJ Brentjens","year":"2007","unstructured":"Brentjens, R. J. et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 5426\u20135435 (2007).","journal-title":"Clin. Cancer Res."},{"key":"3228_CR13","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"key":"3228_CR14","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013).","journal-title":"Sci. Transl. Med."},{"key":"3228_CR15","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra225 (2014).","journal-title":"Sci. Transl. Med."},{"key":"3228_CR16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest."},{"key":"3228_CR17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3228_CR18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3228_CR19","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay, K. A. et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133, 1652\u20131663 (2019).","journal-title":"Blood"},{"key":"3228_CR20","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah, N. N. et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J. Clin. Oncol. 39, 1650\u20131659 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3228_CR21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3324\/haematol.2022.280678","volume":"108","author":"AS Wayne","year":"2023","unstructured":"Wayne, A. S. et al. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia. Haematologica 108, 747\u2013760 (2023).","journal-title":"Haematologica"},{"key":"3228_CR22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch, T. W. et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J. Clin. Oncol. 41, 1664\u20131669 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3228_CR23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3228_CR24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"3228_CR25","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.22.01214","volume":"41","author":"T Wang","year":"2023","unstructured":"Wang, T. et al. Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial. J. Clin. Oncol. 41, 1670\u20131683 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3228_CR26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood.V62.5.1108.1108","volume":"62","author":"L Vodinelich","year":"1983","unstructured":"Vodinelich, L. et al. A monoclonal antibody (WT1) for detecting leukemias of T-cell precursors (T-ALL). Blood 62, 1108\u20131113 (1983).","journal-title":"Blood"},{"key":"3228_CR27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood.V62.4.722.722","volume":"62","author":"M Link","year":"1983","unstructured":"Link, M. et al. A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies. Blood 62, 722\u2013728 (1983).","journal-title":"Blood"},{"key":"3228_CR28","first-page":"170","volume":"3","author":"G Janossy","year":"1989","unstructured":"Janossy, G., Coustan-Smith, E. & Campana, D. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. Leukemia 3, 170\u2013181 (1989).","journal-title":"Leukemia"},{"key":"3228_CR29","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png, Y. T. et al. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 1, 2348\u20132360 (2017).","journal-title":"Blood Adv."},{"key":"3228_CR30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D. et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130, 285\u2013296 (2017).","journal-title":"Blood"},{"key":"3228_CR31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith, E. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 10, 147\u2013156 (2009).","journal-title":"Lancet Oncol."},{"key":"3228_CR32","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","volume":"127","author":"N Jain","year":"2016","unstructured":"Jain, N. et al. Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype. Blood 127, 1863\u20131869 (2016).","journal-title":"Blood"},{"key":"3228_CR33","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood.2023020678","volume":"142","author":"BL Wood","year":"2023","unstructured":"Wood, B. L. et al. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study. Blood 142, 2069\u20132078 (2023).","journal-title":"Blood"},{"key":"3228_CR34","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","volume":"360","author":"C-H Pui","year":"2009","unstructured":"Pui, C.-H. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730\u20132741 (2009).","journal-title":"N. Engl. J. Med."},{"key":"3228_CR35","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","volume":"117","author":"E Coustan-Smith","year":"2011","unstructured":"Coustan-Smith, E. et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 117, 6267\u20136276 (2011).","journal-title":"Blood"},{"key":"3228_CR36","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1073\/pnas.76.11.5829","volume":"76","author":"BF Haynes","year":"1979","unstructured":"Haynes, B. F., Eisenbarth, G. S. & Fauci, A. S. Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets. Proc. Natl Acad. Sci. USA 76, 5829\u20135833 (1979).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3228_CR37","first-page":"331","volume":"19","author":"GD Sempowski","year":"1999","unstructured":"Sempowski, G. D., Lee, D. M., Kaufman, R. E. & Haynes, B. F. Structure and function of the CD7 molecule. Crit. Rev. Immunol. 19, 331\u2013348 (1999).","journal-title":"Crit. Rev. Immunol."},{"key":"3228_CR38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2022016166","volume":"140","author":"BLZ Oh","year":"2022","unstructured":"Oh, B. L. Z. et al. Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients. Blood 140, 156\u2013160 (2022).","journal-title":"Blood"},{"key":"3228_CR39","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia, P. M. et al. Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies. Nat. Med. 23, 1416\u20131423 (2017).","journal-title":"Nat. Med."},{"key":"3228_CR40","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","volume":"133","author":"D S\u00e1nchez-Mart\u00ednez","year":"2019","unstructured":"S\u00e1nchez-Mart\u00ednez, D. et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood 133, 2291\u20132304 (2019).","journal-title":"Blood"},{"key":"3228_CR41","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin, M., Rouce, R. H., Tashiro, H. & Brenner, M. K. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126, 983\u2013992 (2015).","journal-title":"Blood"},{"key":"3228_CR42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","volume":"6","author":"M Mamonkin","year":"2018","unstructured":"Mamonkin, M. et al. Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol. Res. 6, 47\u201358 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"3228_CR43","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","volume":"29","author":"Z Dai","year":"2021","unstructured":"Dai, Z. et al. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. Mol. Ther. 29, 2707\u20132722 (2021).","journal-title":"Mol. Ther."},{"key":"3228_CR44","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan, J. et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J. Clin. Oncol. 39, 3340\u20133351 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3228_CR45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","volume":"16","author":"Y Tan","year":"2023","unstructured":"Tan, Y. et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J. Hematol. Oncol. 16, 34 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"3228_CR46","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","volume":"28","author":"M Zhang","year":"2022","unstructured":"Zhang, M. et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma. Clin. Cancer Res. 28, 2830\u20132843 (2022).","journal-title":"Clin. Cancer Res."},{"key":"3228_CR47","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/10428194.2023.2232496","volume":"64","author":"F Locatelli","year":"2023","unstructured":"Locatelli, F. et al. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R\/R BCP acute lymphoblastic leukemia: a review. Leuk. Lymphoma 64, 1615\u20131633 (2023).","journal-title":"Leuk. Lymphoma"},{"key":"3228_CR48","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"key":"3228_CR49","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","volume":"27","author":"S Li","year":"2021","unstructured":"Li, S. et al. Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management. Clin. Cancer Res. 27, 1242\u20131246 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3228_CR50","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 32, 995\u20131007 (2022).","journal-title":"Cell Res."},{"key":"3228_CR51","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899\u2013910 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3228_CR52","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Rivi\u00e8re, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"3228_CR53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3228_CR54","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"3228_CR55","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu, P. et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood 140, 321\u2013334 (2022).","journal-title":"Blood"},{"key":"3228_CR56","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood.2021015020","volume":"140","author":"A Freiwan","year":"2022","unstructured":"Freiwan, A. et al. Engineering naturally occurring CD7\u2212 T cells for the immunotherapy of hematological malignancies. Blood 140, 2684\u20132696 (2022).","journal-title":"Blood"},{"key":"3228_CR57","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ajh.27094","volume":"98","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am. J. Hematol. 98, 1898\u20131908 (2023).","journal-title":"Am. J. Hematol."},{"key":"3228_CR58","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med. 26, 1569\u20131575 (2020).","journal-title":"Nat. Med."},{"key":"3228_CR59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood-2023-179042","volume":"142","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed\/refractory BCP-ALL. Blood 142, 146\u2013157 (2023).","journal-title":"Blood"},{"key":"3228_CR60","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1200\/JCO.2011.40.5936","volume":"30","author":"AEJ Yeoh","year":"2012","unstructured":"Yeoh, A. E. J. et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia\u2013Singapore acute lymphoblastic leukemia 2003 study. J. Clin. Oncol. 30, 2384\u20132392 (2012).","journal-title":"J. Clin. Oncol."},{"key":"3228_CR61","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2018.78.3050","volume":"36","author":"AEJ Yeoh","year":"2018","unstructured":"Yeoh, A. E. J. et al. Intensifying treatment of childhood B-lymphoblastic leukemia with IKZF1 deletion reduces relapse and improves overall survival: results of Malaysia\u2013Singapore ALL 2010 study. J. Clin. Oncol. 36, 2726\u20132735 (2018).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03228-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03228-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03228-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T08:04:22Z","timestamp":1734077062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03228-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3228"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03228-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"10 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.L.Z.O., N.S., E.C., L.P., S.H.R.L., F.Y., L.K.T., L.Y.A.C., N.T., S.P.C., F.D.B. and M.B. declare no competing interests. E.C.-S.\u2019s spouse receives royalties for patents related to the development of CAR T cell technologies and is a scientific founder and stockholder of Nkarta Therapeutics and Medisix Therapeutics. N.L.B. is a co-inventor in a pending patent for a method to monitor virus-specific T cells in biological samples. A.B. is a co-inventor in a pending patent for a method to monitor virus-specific T cells in biological samples and is a cofounder of Lion TCR. F.L. has been a consultant for Amgen, Bellicum, Novimmune and Vertex and a speaker for BluebirdBio and Amgen. A.E.J.Y. has been a consultant for Amgen. D.C. receives royalties for patents related to the development of CAR T cell technologies and is a scientific founder and stockholder of Nkarta Therapeutics and Medisix Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}